Universal Beteiligungs und Servicegesellschaft mbH Has $4.22 Million Holdings in ANI Pharmaceuticals, Inc. $ANIP

Universal Beteiligungs und Servicegesellschaft mbH increased its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 14.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 64,611 shares of the specialty pharmaceutical company’s stock after acquiring an additional 7,947 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.30% of ANI Pharmaceuticals worth $4,216,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Global Alpha Capital Management Ltd. grew its position in shares of ANI Pharmaceuticals by 17.2% in the second quarter. Global Alpha Capital Management Ltd. now owns 862,090 shares of the specialty pharmaceutical company’s stock valued at $56,251,000 after purchasing an additional 126,500 shares during the last quarter. Aberdeen Group plc boosted its stake in ANI Pharmaceuticals by 76.1% during the 1st quarter. Aberdeen Group plc now owns 419,099 shares of the specialty pharmaceutical company’s stock valued at $28,059,000 after purchasing an additional 181,134 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in ANI Pharmaceuticals by 0.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 238,377 shares of the specialty pharmaceutical company’s stock valued at $15,959,000 after buying an additional 2,220 shares during the last quarter. Nomura Holdings Inc. increased its position in ANI Pharmaceuticals by 1.5% in the 1st quarter. Nomura Holdings Inc. now owns 217,176 shares of the specialty pharmaceutical company’s stock worth $14,540,000 after buying an additional 3,297 shares during the period. Finally, Northern Trust Corp lifted its holdings in shares of ANI Pharmaceuticals by 6.1% during the first quarter. Northern Trust Corp now owns 216,862 shares of the specialty pharmaceutical company’s stock worth $14,519,000 after buying an additional 12,517 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, Director Patrick D. Walsh sold 8,643 shares of ANI Pharmaceuticals stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $86.88, for a total transaction of $750,903.84. Following the completion of the transaction, the director directly owned 61,405 shares of the company’s stock, valued at approximately $5,334,866.40. This trade represents a 12.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Chad Gassert sold 14,642 shares of the company’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $89.07, for a total transaction of $1,304,162.94. Following the completion of the sale, the senior vice president directly owned 158,584 shares in the company, valued at approximately $14,125,076.88. The trade was a 8.45% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 35,399 shares of company stock worth $3,193,081 in the last 90 days. 11.10% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on ANIP shares. Zacks Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 21st. Weiss Ratings reissued a “buy (b-)” rating on shares of ANI Pharmaceuticals in a report on Monday, November 17th. HC Wainwright raised their price target on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the stock a “buy” rating in a research report on Wednesday, September 17th. JPMorgan Chase & Co. upped their price objective on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, September 24th. Finally, Guggenheim increased their target price on shares of ANI Pharmaceuticals from $114.00 to $115.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $99.29.

ANI Pharmaceuticals Trading Up 1.5%

Shares of ANI Pharmaceuticals stock opened at $79.72 on Friday. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $99.50. The firm has a market capitalization of $1.79 billion, a PE ratio of -103.53 and a beta of 0.54. The company has a debt-to-equity ratio of 1.39, a current ratio of 2.54 and a quick ratio of 1.96. The company’s fifty day moving average price is $91.05 and its two-hundred day moving average price is $78.49.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.74 by $0.30. The business had revenue of $227.81 million for the quarter, compared to analyst estimates of $211.92 million. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The firm’s revenue was up 53.6% on a year-over-year basis. During the same period in the previous year, the business earned $1.34 EPS. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. On average, analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.